Title | GC Pharma Reports Q3 2019 Results | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date of registration | 2019-10-30 | ||||||||||||
Attachment File |
| ||||||||||||
Contents | Double-digit profit growth through strong profitable business sales
(1) Results and percentages compare to equivalent 2018 period. Financial Highlights ● Delivered total revenues growth of 4.9% KRW 369.7 billion (Q3 2018: KRW 352.3 billion), all entities revenues grew plus compare to equivalent 2018 period. ● Operating profit increased 30.6% to KRW 36.6 billion (Q3 2018: KRW 28.0 billion), primarily due to a growth by local vaccines segment performance. ● Double-digit profit growth driven by strong profitable business sales like ‘Flu Vaccine’ and ‘Hunterase’. About GC Pharma GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.
# # # |